Nektar Therapeutics (NKTR) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Nektar Therapeutics, with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -4.35x | -1.61x | -0.39x | -1.15x | -4.73x | -6.83x |
| P/B Ratio | 7.94x | 3.15x | 0.82x | 1.15x | 3.64x | 2.82x |
| P/S Ratio | 12.91x | 1.94x | 1.19x | 4.59x | 24.30x | 19.85x |
| Profitability | ||||||
| Gross Margin | 100.0% | 68.8% | 59.3% | 76.5% | 75.6% | 87.3% |
| Operating Margin | -236.8% | -106.9% | -152.5% | -261.0% | -437.8% | -248.5% |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% |
| EBITDA Margin | -234.9% | -88.1% | -269.8% | -351.8% | -453.2% | -257.9% |
| Liquidity | ||||||
| Current Ratio | 4.97x | 4.26x | 6.45x | 8.00x | 9.34x | 9.83x |
| Quick Ratio | 4.97x | 4.26x | 6.14x | 7.72x | 9.15x | 9.70x |
| Leverage | ||||||
| Debt/Equity | 1.66x | 1.69x | 0.90x | 0.36x | 0.21x | 0.14x |
YoY = year-over-year change. Source: FMP..